Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial

Eran Israeli, Ehud Zigmond, Gadi Lalazar, Athalia Klein, Nilla Hemed, Eran Goldin, Yaron Ilan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


AIM: To evaluate the safety and efficacy of oral administration of Alequel™, an autologous proteincontaining colon extract. METHODS: A total of 43 patients were enrolled in a randomized, placebo-controlled, double-blind trial. Patients were orally administered with autologous protein-containing colon extract three doses of autologous study drug per week for 15 wk, for a total of 45 doses. Patients were followed for safety parameters. Remission was defined as a Crohn's disease activity index (CDAI) score of less than or equal to 150. All patients were followed for changes in subsets of T cells by fluorescence-activated cell sorting analysis. RESULTS: Analysis was performed on a total number of evaluable patients of 14 in the study drug group and 15 in the placebo group. Treatment was well tolerated by all patients. No major treatment-related adverse events were reported or observed in any of the treated patients during the feeding or follow-up periods. Between weeks 6 and 9 of the study, six of the 14 (43%) evaluable subjects who received the study drug achieved a CDAI of 150 or lower. In contrast, five of the 15 (33%) evaluable subjects in the placebo group achieved remission. Between weeks 9 and 12, the remission rates were 50% and 33% for the drug group and placebo group, respectively. Among the drug-treated subjects who achieved remission, the effect of the drug was judged as stable in eight of the 14 subjects as measured by at least two CDAI scores indicating remission in the 15-wk treatment period. A decreased percentage of peripheral natural killer T regulatory cells (a decrease of 28% vs an increase of 16%) and an increased ratio of CD4+/CD8+ T lymphocytes (an increase of 11% vs a decrease of 9%) were noted in subjects with a significant clinical response. CONCLUSION: Oral administration of the autologous colonic extract could be a safe and effective for the treatment of patients with moderate to severe Crohn's disease.

Original languageEnglish
Pages (from-to)5685-5694
Number of pages10
JournalWorld Journal of Gastroenterology
Issue number18
StatePublished - 14 May 2015
Externally publishedYes


  • Crohn's disease
  • Immune modulation
  • Natural killer T cells
  • Oral tolerance


Dive into the research topics of 'Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial'. Together they form a unique fingerprint.

Cite this